Regenerative medicine company Collagen Matrix Inc stated on Friday that it has passed US FDA 510(k) market clearance for its innovative line of Mineral Collagen Composite Bioactive Moldable Bone Graft Matrix through its Spine business unit.
The company disclosed that the Bioactive Moldable Bone Graft Matrix is a perfect trio of anorganic carbonate apatite bone mineral, 45S5 bioactive glass and highly purified Type I collagen that can be moulded into putty for filling irregular defect sites. The matrix is an osteoconductive, bioactive, porous implant that allows for bony ingrowth across the graft site. OssiMend Bioactive Moldable is slowly resorbed and replaced by new bone tissue during the natural healing process.
In addition, the matrix is available in various sizes including a unique 25cm long, 40cc strip for complex spine fusion surgeries, revealed the company.
Following the US FDA clearance, the company said OssiMend Bioactive Moldable joins its wide range of implantable collagen and mineral based medical devices.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval